Exploring QSAR on 4-Cyclohexylmethoxypyrimidines as Antitumor Agents for Their Inhibitory Activity of CDK2
Keywords: (CDKS); Antitumor agent; Antitumor agents; Backward elimination methods; Biheterocycles-purine; CDK2 inhibitor; Cancer; DE; Drug's biological activity; Forward-selection; Inhibitory activity; Jurs-RASA; Jurs_RASA; Kinase inhibitors (CKIs); Leave-One Out (LOO-); Metabolic susceptibility; Monoheterocycles pyrimidine; Pyrazole; Pyridine; QSAR; Shadow; Shadow_XYfrac; The dielectric energy (DE); Triazole; Xyfrace
Document Type: Research Article
Publication date: 2010-11-01
- Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.